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(https://www.megasoftware.net). This tree includ-
ed isolates from other countries in Asia downloaded 
from PubMLST (https://pubmlst.org); the isolate in 
this study was most closely related to ST175 from 
Thailand (Appendix Figure 2) (6).
The accuracy of the identifications made by 
VITEK 2 (63%–81%), Phoenix (0%–28%), and API 
20NE (37%–99%) systems varied substantially (7,8). 
Zakharova et al. found that commercially available 
biochemical identification systems commonly mis-
identified B. pseudomallei as Chromobacterium vio-
laceum or B. cepacia complex (9). We found that al-
though the isolate in this study was misidentified by 
multiple systems, most systems accurately identi-
fied the genus. MALDI-TOF mass spectrometry is a 
rapid, accurate, and highly reproducible technique 
for bacterial identification. Several studies have ex-
plored the potential of MALDI-TOF mass spectros-
copy for the identification of B. pseudomallei. We 
prefer the Bruker Biotyper system, which is more 
accurate because the VITEK databases lack refer-
ence spectra for B. pseudomallei (10). In conclusion, 
scientists must be aware of the potential misidenti-
fication of B. pseudomallei by automated identifica-
tion systems, especially those in regions to which B. 
pseudomallei is not endemic.
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A 48-year-old man in Switzerland sought treatment for a 1-year history of progressive dyspnea, cough, 
20-kg weight loss, and increased sweating; he was re-
ceiving oxygen therapy. Results of previous consulta-
tions had been inconclusive. An HIV screening test was 
negative. Medical history included hyperreflexia, de-
pression, and chronic hepatitis B. The man had stopped 
cocaine inhalation and heroin consumption 20 years 
earlier but continued smoking cigarettes and cannabis. 
Regular medications included omeprazole and trimip-
ramine. Except for a short trip to Greece and Italy many 
years before, the patient reported no foreign travel.
In the absence of travel history to an endemic 
area, histoplasmosis was not initially considered at 
the time this patient sought treatment. A prolonged 
diagnostic process and delayed treatment initiation 
had meanwhile resulted in significant deterioration 
of health, including need for home oxygen therapy, 
and loss of ability to work. Meanwhile, the patient 
was cachectic and had clubbing on his fingers and 
toes. Spirometry revealed nearly normal dynamic 
lung volumes. Forced expiratory volume was 3 L 
(75%) and forced vital capacity 4.1 L (83%), but dif-
fusion capacity was severely impaired; diffusing 
capacity for carbon monoxide was 20%. A 6-minute 
walking test was limited to 400 m (59% predicted), 
initial oxygen saturation dropping from 90% to 78%. 
A chest computed tomography (CT) scan showed a 
diffuse reticulonodular pattern with predominantly 
upper lung opacifications and bronchiectases indi-
cating fibrotic lung disease (Figure, panels A, B). Re-
versed halo signs and right upper lobe nodules were 
found. Bronchoscopy results including bronchoalve-
olar lavage were unremarkable. Initial sampling with 
microbiological screening was negative. 
Differential diagnoses included toxic lung damage 
or other interstitial lung disease, (e.g. atypical presen-
tation of Langerhans cell histiocytosis or sarcoidosis). 
A wedge biopsy showed predominantly upper-lobe 
fibrosis and multiple, confluent, necrotizing granu-
lomas harboring yeasts, establishing the diagnosis 
of pulmonary histoplasmosis (Appendix Figure, 
https://wwwnc.cdc.gov/EID/article/27/3/19-1831-
App1.pdf). 
A qualitative immunodiffusion test (IMMY, 
https://www.immy.com) was positive for antibodies 
in plasma, but an antigen immunoassay for Histoplas-
ma in urine (IMMY) was negative; a beta-1,3-D glu-
can test (Fungitell, https://www.fungitell.com) was 
highly positive (>500 pg/mL; limit <80 pg/mL). At 
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In Europe, pulmonary histoplasmosis is rarely diagnosed 
except in travelers. We report a probable autochthonous 
case of severe chronic pulmonary histoplasmosis in an 
immunocompetent man in Switzerland without travel his-
tory outside of Europe. Diagnosis was achieved by histo-
pathology, fungal culture, and serology, but the source of 
the infection remains speculative. 
Figure. Chest computed 
tomography (CT) images at the 
level of the upper third and the 
lower third of the lung in a patient 
with pulmonary histoplasmosis, 
Switzerland. A, B) Initial CT 
shows diffuse reticulonodular 
pattern with ground glass 
opacifications, predominantly 
located in the upper two thirds 
of the lungs, and several areas 
with reverse halo signs (red 
arrows). C, D) Follow-up CT scan 
exhibited reduced ground-glass 
opacities and a regression of the 
micronodules. The reversed halos 
showed complete regression. CT, 
computed tomography.
prolonged incubation (14 days, 30°C), a fungal culture 
on BD Difco dehydrated culture media Sabouraud 
brain heart infusion agar base (with chloramphenicol 
and cycloheximide) (https://www.bd.com) showed 
flat, floccose to powdery, whitish growth. We found 
microscopically large, tuberculated macroconidia 
(7–12 µM) and small round microconidia on short, 
lateral pegs consistent with Histoplasma capsulatum. 
Matrix-assisted laser desorption/ionization time-of-
flight mass spectrometry (MALDI Biotyper, https://
www.bruker.com) results confirmed the diagnosis. 
Molecular identification was done using an in-house 
panfungal PCR assay with consecutive sequence anal-
ysis. We used the internal transcribed spacer region 
as target and internal transcribe sequences 1 and 2 for 
amplification primers (1,2). Microsynth AG (https://
www.microsynth.ch) performed DNA sequencing. 
Sequences produced alignments of H. capsulatum in 
BLAST (https://blast.ncbi.nlm.nih.gov/Blast.cgi) 
and CBS (Centraalbureau voor Schimmelcultures; 
Westerdijk Institute, https://wi.knaw.nl) databases. 
Some radiologic features were unusual. There was 
no cavity formation (3), and the reverse halo sign has 
rarely been described in chronic pulmonary histoplas-
mosis (4). However, bullae seen on the scan, previously 
observed in patients with heavy tobacco use and un-
derlying lung disease, were compatible with the diag-
nosis. Despite slow growth, cultures for histoplasmosis 
together with histopathology remain the diagnostic 
standard (1). Panfungal PCR is sensitive, but its perfor-
mance depends on internal validation processes (2). Im-
munocompetence and lack of dissemination could ex-
plain repeatedly negative urine antigen testing. (1).
Underlying lung disease likely predisposed this 
patient for severe disease. However, his clinical re-
sponse to treatment was remarkable. We initiated 
antifungal treatment with liposomal amphotericin 
B and oral prednisolone. After a few days, the pa-
tient improved substantially, and oxygen supple-
mentation was stopped. At 10 days, therapy was 
switched to oral itraconazole. Steroid treatment was 
continued at a tapered dosage over 3 months, with 
trimethoprim/sulfamethoxazole used as Pneumo-
cystis jirovecii pneumonia prophylaxis. At 3-month 
follow-up, the patient had improved considerably. 
Repeated spirometry was nearly normal, showing 
persistent impairment of diffusion capacity. Follow-
up chest CT scan (Figure 1, panels C, D) showed 
regression of ground-glass opacities and micronod-
ules; the reversed halos had disappeared. Overall, 
optimal treatment duration remains unclear (5), but 
because of probable underlying preexisting lung 
disease, persistent pathological findings from CT, 
and continued desaturation under exercise, continu-
ing treatment for >12 months seemed necessary.
The source of infection for this patient remains 
speculative. However, possible risk exposures were 
guano from flying bats in the garden (6), previous use 
of organic fertilizer possibly containing histoplasma 
(7), and regular work-related unpacking of fruits and 
spices from straw-filled boxes from West Africa, al-
though H. capsulatum var. capsulatum is less common 
in that region (8). 
In addition to previous findings of histoplasmosis 
in badgers (9), this case confirms the likely environmen-
tal occurrence of H. capsulatum in Switzerland. Although 
diagnoses of autochthonous histoplasmosis have been 
rare, and few autochthonous cases have been described 
(10), our finding of a probable autochthonous case of 
chronic pulmonary histoplasmosis in an immunocom-
petent male in Switzerland highlights the incomplete 
understanding of histoplasmosis endemicity and indi-
cates that it has likely been underestimated in Europe. 
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In 1905, Samuel Taylor Darling serendipitously iden-tified a protozoan-like microorganism in an autopsy 
specimen while trying to understand malaria, which was 
prevalent during the construction of the Panama Canal. 
He named this microorganism Histoplasma capsulatum 
because it invaded the cytoplasm (plasma) of histiocyte-
like cells (Histo) and had a refractive halo mimicking a 
capsule  (capsulatum), a misnomer.
Histoplasma capsulatum, a dimorphic fungus, now 
belongs to Kingdom Fungi and causes histoplasmosis 
(Darling’s disease) through inhalation of spores found in 
soil and bird droppings. The fungus thrives in the cen-
tral and eastern parts of United States, especially around 
the Ohio and Mississippi River valleys, and in South 
America, Africa, Asia, and Australia. Three varieties ex-
ist globally: H. capsulatum var. capsulatum, H. capsulatum 
var. duboisii, and H. capsulatum var. farciminosum.
Figure. Numerous, capsulated yeast cells (shown in 
pink) of Histoplasma capsulatum in a bone marrow 
aspirate (Giemsa-stained, original magnification 
×400). Source: Shivaprakash Rudramurthy, PGIMER, 
Chandigarh, India.
